NDAORALTABLET, CHEWABLE2 Generics Approved
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
60/100
Clinical Trials
18
Data completeness
3/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYVANSE (lisdexamfetamine dimesylate) is an oral CNS stimulant prodrug approved in 2017 for the treatment of ADHD and binge eating disorder. The drug is converted in the body to active dexamphetamine, providing a delayed onset and extended duration of action compared to immediate-release formulations. It is available as tablets and chewable formulations.
$139MPart D
PeakPeak lifecycle stage with significant Part D penetration signals a mature, stable franchise requiring focus on market defense and reimbursement optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
Started Sep 2025
105 enrolled
Obesity and OverweightBinge Eating Disorder
Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder
Started Jun 2019
150 enrolled
Binge-eating Disorder
Open Label Extension in Adults With Binge Eating Disorder (BED)
Started Aug 2012
604 enrolled
Binge Eating Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
Started Apr 2012
464 enrolled
Attention-deficit/Hyperactivity Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
Started Apr 2012
549 enrolled
Attention-deficit/Hyperactivity Disorder
Worked on VYVANSE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.